Buy Kopran; target of Rs 25: Firstcall Research

Firstcall Research is bullish on Kopran and has recommended buy rating on the stock with a target of Rs 25 in its December 18, 2012 research report.

“Kopran is the group company of Parijat Enterprises. Kopran is currently an integrated Pharmaceutical Company manufacturing a large range of products. It manufactures both Active Pharmaceutical Ingredients and Finished Dosage Forms. Kopran’s products are registered globally and its facilities match best of international standards and are approved by various Regulatory authorities. Kopran focused on improvement in technology and new products duly integrated through their sophisticated Research & Development department.”
“Kopran is currently an integrated Pharmaceutical Company manufacturing a large range of products. It manufactures both API and Finished Dosage Forms has reported its financial results for the quarter ended 30th Sep, 2012. The company’s net profit jumps to Rs.32.30 millions against Rs.6.10 millions in the corresponding quarter ending of previous year, an increase of 429.51%. Revenue for the quarter rose 31.22% to Rs.647.30 millions from Rs.493.30 millions, when compared with the prior year period. Reported earnings per share of the company stood at Rs.0.83 a share during the quarter, registering 429.51% increase over previous year period. Profit before interest, depreciation and tax is Rs.90.60 millions as against Rs.52.30 millions in the corresponding period of the previous year.”
“Kopran Ltd has launched various new products in the chronic and CNS Segments as well as new emerging acute segments like Oncology and Penems. Simultaneously various drug Master Files and Dossiers of Finished Dosage Forms are being filed in the Regulated markets. Also the facilities are being expanded to launch new products. The second quarter witnesses a healthy increase in overall sales as well as profitability on account of new product development and global presence with quality products. We expect that the company surplus scenario is likely to continue for the next three years, will keep its growth story in the coming quarters also. We recommend buy in this particular scrip with a target price of Rs.25 for medium to long term investment,” says Firstcalll Research report. Public holding more than 90% in Indian cos Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. To read the full report click on the attachment

Read More